Related Experiment Video
Updated: Dec 12, 2025
An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
Published on: October 10, 2025
Available Therapies for Patients with Neurofibromatosis-Related Nervous System Tumors
Roy E Strowd1,2
1Department of Neurology, Internal Medicine, Section on Hematology and Oncology, and the Translational Sciences Institute, Wake Forest School of Medicine, 1 Medical Center Boulevard, Winston Salem, NC, 27157, USA. rstrowd@wakehealth.edu.
Opinion Statement:
Though the majority of nervous system tumors are sporadic, several clinically relevant genetic syndromes are associated with a predisposition to tumors of the central and peripheral nervous system including neurofibromatosis type 1 (NF1), type 2 (NF2), and schwannomatosis (SWN). These represent prototypical tumor suppressor syndromes where loss of a tumor suppressor gene-protein impairs the cell's ability to regulate cell proliferation. While clinical manifestations vary widely for each of these syndromes, tumors arising in the peripheral nerve sheath are a unifying feature. Clinical clues should prompt the clinician to recognize the underlying genetic syndrome and screen for associated tumors including, among others, plexiform neurofibromas and gliomas in NF1 and vestibular schwannomas, meningiomas, and spinal ependymomas in NF2. Improvements in mechanistic understanding of how the genetic mutations that underlie these syndromes contribute to tumor formation have led to new advances in targeted therapies. MEK inhibitors have shown promise for treating progressive plexiform neurofibromas in NF1. Bevacizumab has been shown to improve hearing and treat vestibular schwannomas in NF2. This article reviews the currently available data on management of tumors associated with these three syndromes.
Insights
Genetic syndromes like neurofibromatosis (NF1, NF2) and schwannomatosis predispose individuals to nervous system tumors. Targeted therapies, including MEK inhibitors and bevacizumab, show promise for managing these conditions.
Area of Science:
- Oncology
- Genetics
- Neurology
Background:
- Several genetic syndromes, including neurofibromatosis type 1 (NF1), type 2 (NF2), and schwannomatosis (SWN), confer a predisposition to central and peripheral nervous system tumors.
- These syndromes exemplify tumor suppressor conditions where gene-protein loss disrupts cell proliferation control.
- Peripheral nerve sheath tumors are a common feature across these distinct genetic syndromes.
Purpose of the Study:
- To review current data on the management of tumors associated with NF1, NF2, and SWN.
- To highlight clinical clues for recognizing these genetic syndromes and associated tumors.
- To discuss advances in targeted therapies based on mechanistic understanding of tumor formation.
Main Methods:
- Review of current literature on tumor management in NF1, NF2, and SWN.
- Analysis of clinical manifestations and diagnostic indicators for these syndromes.
- Evaluation of emerging targeted therapies and their efficacy.
Main Results:
- Tumors such as plexiform neurofibromas and gliomas are associated with NF1.
- Vestibular schwannomas, meningiomas, and spinal ependymomas are linked to NF2.
- MEK inhibitors show promise for NF1 plexiform neurofibromas; bevacizumab aids NF2 vestibular schwannomas and hearing.
Conclusions:
- Early recognition of genetic syndromes is crucial for timely tumor screening and management.
- Targeted therapies are advancing treatment options for tumors in NF1, NF2, and SWN.
- Continued research into the underlying mechanisms of these syndromes will drive further therapeutic innovation.
Related Concept Videos
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers